Estimation of Skeletal Plutonium Levels Based on DTPA-induced Radionuclide Excretion in Feces

Mh, Bhattacharyya; Ra, Guilmette; Dp, Peterson; Fc, Chao; Lindinbaum, A

doi:10.1097/00004032-197806000-00003

Cited by 6 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The initial blood compartment uptake indicates that the first day is important with respect to DTPA effectiveness. Chelation treatment is normally not recommended for an insoluble (Type S) intake, where a lung lavage may be advised for significant intakes (Bhattacharyya et al 1978a;USDOE 2008).…”

Section: Lung Retentionmentioning

confidence: 99%

Development of the Plutonium-DTPA Biokinetic Model

Konzen

Brey²

2015

Health Physics

View full text Add to dashboard Cite

Estimating radionuclide intakes from bioassays following chelation treatment presents a challenge to the dosimetrist due to the observed excretion enhancement of the particular radionuclide of concern where no standard biokinetic model exists. This document provides a Pu-DTPA biokinetic model that may be used for making such determination for plutonium intakes. The Pu-DTPA biokinetic model is intended to supplement the standard recommended biokinetic models. The model was used to evaluate several chelation strategies that resulted in providing recommendations for effective treatment. These recommendations supported early treatment for soluble particle inhalations and an initial 3-day series of DTPA treatments for wounds. Several late chelation strategies were also compared where reduced treatment frequencies proved to be as effective as multiple treatments. The Pu-DTPA biokinetic model can be used to assist in estimating initial intakes of transuranic radionuclides and for studying the effects of different treatment strategies.

show abstract

Section: Lung Retentionmentioning

confidence: 99%

Development of the Plutonium-DTPA Biokinetic Model

Konzen

Brey²

2015

Health Physics

View full text Add to dashboard Cite

show abstract

“…The DCF 21 or dose conversion factor is the effective dose coefficient for inhalation [e inh (50) When discussing the MDD for a radiobioassay program it is convenient to have a single value. This provides correlation between the MDD for a particular analysis at a specific time interval, (MDD(t)), to the performance objective.…”

Section: Minimum Detectable Dose For Routine Radiobioassaymentioning

confidence: 99%

“…Most of this increase is assumed to come from the chelation of free plutonium in the blood; that is, the increase in urinary excretion reflects unincorporated plutonium. Excretion of plutonium in the bile also increases but reflects the removal of plutonium that was incorporated in the liver 50 . As a rough approximation for an acute injection intake of plutonium, it is assumed that the feces excretion rate will be ~1/3 of the urinary excretion rate following chelation therapy.…”

Section: Effect Of Chelation On Feces Excretionmentioning

confidence: 99%

See 1 more Smart Citation

Sandia National Laboratories Internal Dosimetry Technical Basis Manual (Rev 4)

Hayes

Elliott

2014

View full text Add to dashboard Cite

Urinary Excretion of Plutonium in Mayak Workers During and After Ca-Dtpa Administration

Sokolova¹,

Суслова²,

Miller³

2021

Radiation Protection Dosimetry

View full text Add to dashboard Cite

Chelation therapy is sometimes used after potential exposures to plutonium to increase urinary excretion of the radionuclide to improve the accuracy of bioassay measurements. The purpose of this report is to describe the enhancement of urinary excretion of plutonium during and after the administration of the trisodium salt of calcium diethylenetriaminepentaacetate (Ca-DTPA) daily for 3 d to a group of male and female plutonium workers from the Mayak Production Association in Ozyorsk, Russia. One-hundred and two cases (18 females and 84 males) were selected where urinary contents of plutonium, prior to chelation, exceeded the detection threshold. Daily urine collections were obtained during the 3 d of Ca-DTPA treatments. In addition, 58 of these cases had urine bioassays at 1–45 d after chelation. The daily enhancement over baseline values excretion of plutonium was found to be 50.4×/1.4 (geometric mean and geometric standard deviation); 58.9×/1.2; 72.9×/1.4 in the first, second and third days of Ca-DTPA administration. The mean enhancement for the 3-d period was 60.1×/1.7. The rate of plutonium excretion from 1 to 45 d after chelation decreased with a half-period of 3.9 d and the chelation enhancement factor (Кenh-i) is described by the function Кenh-i = (0.79 ± 0.24) + (42.9 ± 1.2) × e−(0.18 ± 0.01) × day.

show abstract

Estimation of Skeletal Plutonium Levels Based on DTPA-induced Radionuclide Excretion in Feces

Cited by 6 publications

References 4 publications

Development of the Plutonium-DTPA Biokinetic Model

Development of the Plutonium-DTPA Biokinetic Model

Sandia National Laboratories Internal Dosimetry Technical Basis Manual (Rev 4)

Urinary Excretion of Plutonium in Mayak Workers During and After Ca-Dtpa Administration

Contact Info

Product

Resources

About